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Stroke in Women: Disparities and Outcomes
Rebecca W. Persky, Lisa Christine Turtzo, and Louise D. McCullough
Departments of Neurology and Neuroscience, University of Connecticut Health Center, 263
Farmington Avenue, Farmington, CT 06030, USA
Abstract
Stroke is the leading cause of disability in the United States and affects 15 million people worldwide.
Studies performed in various parts of the world have found differences between sexes in stroke
incidence, prevalence, mortality, and outcomes. Although men are at higher risk of stroke for most
age groups below age 85 years, after this age the incidence reverses dramatically, with women being
much more at risk. Furthermore, recent studies suggest that women have worse recovery than men
post-stroke. Many aspects of recovery may influence this outcome, including sex-specific
comorbidities, aggressiveness of acute treat-ment, prevention therapies, and varying degrees of social
support and rates of depression. It is important to further define and investigate sex differences in
stroke incidence, care, treatment, and outcomes to improve functional recovery in women.
Introduction
Stroke is the third leading cause of death after heart disease and cancer, and the leading cause
of disability in the United States. During most of the life span, men have a higher incidence of
stroke than women, but over the age of 85 years more women suffer strokes (Fig. 1)[1•], leading
to an excess of disability and mortality in older women. Several studies suggest that women
may be treated less aggressively for primary and secondary stroke prevention and acute stroke
compared with men. Women also have higher rates of depression and lower quality of life than
men and are more likely to require assistance after a stroke, even when controlling for factors
such as age and premorbid function. As our population ages, elderly women will become an
increasing proportion of the stroke population, making it crucial to identify and address these
disparities. Additionally, sex differences may exist in the efficacy of pharmaceutical agents
used for stroke prevention and treatment or in the effectiveness of rehabilitation. Identifying
these differences will allow us to tailor therapy to the specific needs of women and enhance
functional outcomes. This article discusses recent evidence demonstrating the existence of sex
disparities in stroke care and recovery. Possible differences in “sex-based biology” could
account for some of these disparities. We hope that a better understanding of these differences
will allow for more appropriate treatment and prevention for women and men.
Incidence and Prevalence
Historically, male sex has been considered a risk factor for stroke; however, because of the
longer life expectancy in female individuals, the majority of stroke deaths now occur in women
[2]. Every year 55,000 more women suffer a stroke than men. Although stroke incidence rates
are higher for men than women in most age groups, after the age of 85 years significantly more
women suffer strokes than men (Table 1,Fig. 1) [1•]. These sex differences will be magnified
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as our population ages, so that by the year 2050, 60% of stroke patients will be women [2].
Addition-ally, more women than men suffer recurrent strokes within 5 years after their first
stroke, a finding seen in younger (40–69 years old, 22% vs 33%) and elderly (>70 years old,
28% vs 33%) patients [3••]. Prevalence rates for stroke follow a similar pattern. In an age-
adjusted study of pooled data from 13 prevalence studies, stroke is 41% more prevalent in men
than women, but reverses dramatically over the age of 85 years [4]. However, this epidemiology
may be changing because stroke incidence is rising in younger women. A recent study found
that more women 45 to 54 years of age suffer strokes than men in the same age group, which
may be indicative of growing rates of obesity and metabolic syndrome in middle-aged women
[5].
Severity, Mortality, and Case Fatality
Data vary as to whether there is a difference in stroke severity between men and women. Some
studies indicated that women suffer more severe strokes than men [4,6], whereas others found
no significant difference between the sexes [7,8]. However, most researchers agree that
disability, mortality, and case fatality are greater in women than men, which are confounded
by the overall older age of women at stroke onset [2]. As of 2005, stroke accounted for 1 of
every 17 deaths in the United States, with women accounting for 60% of stroke deaths (Table
1)[1•]. This disproportionate mortality rate in women is mostly because of the older age of
women at stroke occurrence and the fact that women live longer than men. Age-adjusted studies
indicate a slightly lower mortality rate for women overall [2], although over the age of 85 years,
women still have a 15% higher stroke mortality than age-matched men [9].Multiple studies
indicate that the excess of women who die from stroke is increasing dramatically [2,9].
Various studies also have looked at case fatality rates by sex and found no significant difference
between men and women or that women had slightly higher rates [2]. A compilation of multiple
case fatality studies showed that women have a higher rate of fatality in 26 out of 31 studies
that followed patient outcome for 28 or 30 days post-stroke [4]. The International Stroke Trial
found higher case fatality rates for women at 14 days and at 6 months post-stroke, but when
differences such as age and comorbidities were normalized between the sexes, the higher
fatality in women was negated at 6 months post-stroke [3••]. The Women’s Health
Organization MONICA Project performed a 28-day monitoring of stroke patients and found
women to be equivalent or higher than men in case fatality rates [2]. A recent Framingham
Heart Study found no significant difference in case fatality rates for 30-, 90-, and 180-day
studies [7]. Baseline differences between men and women (eg, age, comorbidities, severity,
and pre-stroke disability) cause much of the excess of mortality in women. However, even
when controlling for these factors, women continue to have poorer functional outcomes after
stroke [10].
Symptoms, Stroke Subtype, and Presentation
Studies have shown that women differ from men in pre-existing comorbidities, stroke subtype,
and symptoms on presentation. Women are more likely to have a past medical history of
hypertension and atrial fibrillation (AF), whereas men are more likely to present with heart
disease, dyslipidemia, diabetes, myocardial infarction, peripheral artery disease, tobacco and
alcohol use [2,8,11]. AF itself is a risk factor for stroke with an age-adjusted risk ratio of 4.8
[3••], but a sex disparity is observed in stroke risk for men and women with AF. Although men
have a higher incidence of AF at all age groups [12], women with nonvalvular AF have double
the risk of stroke than men with the same condition [2]. Women with coronary artery disease
and AF have five times the risk of stroke as a healthy individual, whereas risk only doubles in
men with both these risk factors [11]. In a study of 780 AF patients on anticoagulation therapy,
40 patients suffered ischemic events, with a relative risk ratio in female versus male patients
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of 2.0 (95% CI, 1.3–3.1) [13]. Additionally, women suffered more severe and disabling strokes
than men despite the same anticoagulation level [13]. A study that monitored patients who had
recently been taken off anticoagulants showed that women had a higher annual incidence of
thromboembolic complications than did men [3••]. It is unfortunate that although women are
at higher risk for a stroke if they have AF, many women do not perceive themselves to be at
risk. A recent study surveyed 215 predominately white, high-earning, well-educated women
whether they considered their personal medical conditions as risk factors for stroke [14]. Only
5.4% identified AF as a risk for stroke, and only 15.5% identified their heart disease as a risk
factor for stroke [14]. Judging from this data, it is vital to educate high-risk patients about the
possible medical consequences of their disease, espe-cially because we now have treatment
options for patients with acute stroke.
Similar to reports in the cardiology literature [15], women are more likely to present at hospitals
with “nontraditional” stroke symptoms [16]. Of 461 patients in Michigan, 51.8% of women
reported nontraditional symptoms, most commonly mental status change, compared with
43.9% of men. The odds of reporting at least one nontraditional symptom was 1.42 times greater
in women than in men [16]. Other nontraditional symptoms include pain, lightheadedness,
headache, and other unclassifiable neurologic and non-neurologic symptoms [3••,16].
However, other studies found no differences between sexes in traditional stroke symptom
presentation [17]. Another study found that although women may more often present with
nontraditional symptoms, this sex difference did not lead to any differences or delays in
treatment [18••].
Although data vary on the subject of sex differences in stroke subtype, it has been noted that
women suffer more cardioembolic strokes than men, [3••,4,17], and have higher rates of
subarachnoid hemorrhage [4]. As far as other stroke subtypes, data are variable; some show
no difference between men and women [7], whereas others suggest that men are more likely
to have large vessel and small vessel strokes, as well as intracerebral hemorrhage [4]. It is
important to clarify any differences in etiology because they could lead to changes in acute
management or preventive measures.
Prevention
Differences in Response to Pharmacologic Agents
Pharmacologic agents that are commonly used to prevent stroke can display sex-specific effects
[3••]. This may reflect differences in drug metabolism or dosing, sex-specific steroid
interactions, or other sex-specific differences. It is important to consider the organizational
effects of steroids (in prenatal and neonatal life) and activational effects (throughout the life
span, beginning at the pubertal surge until menopause) as well as the effects of the sex
chromosomes themselves on stroke. In development, the chromosomal sex (XX or XY)
programs cells to respond in a certain way to ischemic stress. Neonatal female subjects appear
to have an “intrinsic” neuroprotective phenotype, likely due in part to early hormonal exposure
but possibly also due to contributions from genes on the X chromosome [19]. Interestingly,
women with Turner syndrome (having only one X chromosome) have higher rates of stroke,
hypertension, and heart disease, even after they are supplemented with estrogen [20]. This
suggests that the presence of a second X chromosome reduces stroke risk, or that the Y
chromosome enhances ischemic sensitivity. Emerging data have shown that numerous genes
on the second X chromosome escape “inactivation” and may contribute a large degree of
heterogeneity in stroke risk and ischemic damage [21]. The “chromosomal” basis of stroke
sensitivity and hormonal influences on genetic risks will be a major area of research in the
future.
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Primary Prevention
Investigators only recently began to examine sex differences in the efficacy of pharmacologic
agents used for treating or preventing stroke. The Women’s Health Study examined aspirin as
a primary preventive agent for cardiovascular disease in healthy women over age 45 years
[3••]. The risk of ischemic stroke was reduced by 24% in the treated cohort, but no benefit was
found for cardiac risk. A similar male-only cohort (Physicians’ Health Study) found a
significant risk reduction in a man’s risk for cardiac disease, but surprisingly no risk reduction
in stroke [3••]. These findings were confirmed in a recent meta-analysis of six randomized
trials; women had a 17% reduced risk of ischemic stroke when taking aspirin for primary
prevention with no change in ischemic stroke risk in men [2]. In contrast, the risk of myocardial
infarction was reduced by 32% in men, with no change in women’s myocardial infarction risk
with aspirin treatment. Why phenotypic variance in vascular disease manifestations is seen is
not yet known [2]. Examination of other antiplatelets and pharmacologic agents for possible
differential effects is important to treat patients optimally and efficiently.
Secondary Prevention
Different risk factor profiles in men and women may necessitate different approaches to
secondary prevention of stroke. Women are more likely to have hypertension and AF compared
with men [2,8,11]. Despite these risk factors, according to one recent study, women are less
likely to receive angiotensin-converting enzyme inhibitors after stroke [22]. A discrepancy in
the current literature exists regarding whether antiplatelets and anticoagulants are administered
differently to men and women after stroke [2,8,22]. Although some studies found no differences
[1•,13], studies from other geographic regions found different prescribing practices for men
and women [2,8,17]. These differences may reflect different geographic practice patterns.
Regardless of biologic sex, patients with risk factors such as hypertension and AF should be
treated appropriately to reduce their risk of stroke.
Lipids are generally more aggressively treated in men in the hospital after stroke, perhaps
because of the higher incidence of dyslipidemia in men than women at stroke presentation.
This is mirrored by the higher percentage of men discharged on statins than women [22];
however, other researchers found men and women are equally likely to be treated with statins,
suggesting this may be secondary to geographic variability in prescribing patterns [2]. In
addition, women tend to have higher high-density lipoprotein levels than men, and low-density
lipoprotein levels often do not begin to rise until after menopause (an average of 2 mg/dL
between the ages of 40–60 years) so age becomes an important confounder in these studies
[23], and lower rates, especially in younger women, may be appropriate. Importantly,
triglycerides may be a more important marker for vascular risk (high triglyceride/low high-
density lipoprotein; metabolic syn-drome), although the specific effects on stroke risk have not
been evaluated. It is clear that women do benefit from statin therapy as much as men for the
prevention of major coronary events [24], and it is likely that the same holds true for stroke.
Sex, Hormones, and Hormone Replacement Therapy
Preclinical data are emerging that suggest that ischemic stress triggers different cell death
pathways in male (XY) and female (XX) cells [3••]. If this holds true for clinical populations
as well, different “sex-specific” pharmacologic therapies may need to be developed, as an agent
may protect one sex and be detrimental in another if the incorrect pathway is targeted. Much
of this work has been performed at the bench [25•], and the relevance for patients with stroke,
if any, is not yet known. More is known regarding the influence of gonadal hormones on stroke,
primarily from large studies performed in the past 5 years [25•]. Pregnancy is also a unique
“risk factor” for women, as rates of ischemic (RR, 0.7) and hemorrhagic (RR, 2.5) stroke rise
dramatically in the peripartum period [26]. Women with preeclampsia are at higher risk of
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stroke for at least 1 year after pregnancy, suggesting that hormonal factors can influence long-
term risk [27]. Children born of preeclamptic mothers also experience a higher risk of stroke
as adults [28].
Premenopausal women are less likely to suffer a stroke than men of similar ages or
postmenopausal women. This difference in epidemiology has been ascribed to the protective
effects of estrogen exposure [26,29]. Studies using rodent models have repeatedly shown that
females have less damage after an induced stroke than males [3••]. This protection can be
reversed with ovariectomy and restored with estrogen treatment [3••].
However, large clinical trials performed over the past 5 years have failed to translate the
beneficial effects of estrogen into the population at risk for stroke, postmeno-pausal women.
There are numerous potential explanations for these discrepancies, including the timing, dose,
and duration of hormone exposure, as well as limitations of our preclinical models (ie, acute
treatment after an induced stroke, the use of young animals, primarily rodent studies). For
example, the WHI found an increased incidence of stroke in healthy women exposed to
hormone replacement therapy (HRT) compared with placebo [30]. However, most women who
took HRT in previous observational studies began treatment early in menopause for control of
estrogen-deficiency symptoms, whereas WHI subjects began HRT at an average of 12 years
after the menopause (mean age for HRT, 63.3 years) [31]. In addition, a recent study by
Lisabeth et al. [32] found that women who end their menses between the ages of 42 and 54
years had a lower risk of stroke (hazard ratio, 0.50) than those who went through early
menopause before the age of 42 years [32], implying that duration of steroid exposure does
influence risk.
Estrogen has adverse inflammatory effects in areas of established atherosclerosis [3••,33,
34•], promoting thrombosis and inflammation in diseased vessels, particularly at
supraphysiologic doses. These detrimental effects were seen in the Nurses’ Health Study; high
doses of estrogen were less protective against vascular disease and promoted stroke risk [35].
The proinflammatory effects are also reflected in C-reactive protein levels, a marker of vascular
risk. C-reactive protein was elevated 65% in healthy women (>65 years of age) exposed to 12
weeks of a high dose of estrogen (1 mg/d), and remained 92% higher than placebo even 12
weeks after treatment was discontinued [36].
Because HRT/estrogen replacement therapy’s vascular properties may shift from
antiatherogenic to proatherogenic in diseased vessels, the KEEPS has been designed to
investigate whether initiation of low-dose HRT at an earlier stage of atherosclerosis is
beneficial. This trial is a randomized, multicenter trial of HRT in recently menopausal women
using oral or transdermal estrogen with intermittent micronized progesterone. Women will be
followed for a 5-year period, and common carotid intimal medial thickness as measured by B-
mode ultrasound will be used as the primary end point [33]. Additionally, the ELITE is
currently enrolling patients. In this trial, postmenopausal women will receive oral 17beta-
estradiol or placebo according to their number of years since menopause. It is expected that
estrogen will reduce the progression of early atherosclerosis if initiated soon after menopause
when the vascular endothelium is relatively healthy.
Acute Treatment
The establishment of Get with the Guidelines-Stroke (GWTG-Stroke) has facilitated the
examination of possible sex differences in stroke care in the inpatient setting. Women have
longer waiting times once they arrive at the emergency room and receive less intensive
treatment and therapeutic workup once they are admitted [10,18••,22]. One recent study found
that women had 11% longer door-to-doctor times and 15% longer door-to-image times as men
[18••]. These differences have potentially enormous consequences because we have only one
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drug to treat patients with acute ischemic stroke, tissue plasminogen activator (tPA). This agent
has an extremely short therapeutic window, and even short delays could make patients
ineligible. One possible reason for this disparity is the atypical presentations seen in women
presenting with stroke, delaying identification of stroke patients [16], although this seems
unlikely based on recent data [28]. Women also may experience pre-hospital delay. One study
found a three-fold risk of delay in reaching the hospital in women experiencing a stroke
compared with men [37], which could increase rates of ineligibility for thrombolytic treatment.
Several studies tracking women’s awareness of heart disease suggest that, although improved,
a significant gap still exists between the perceived and actual risk of cardiovascular disease
and stroke, as well as social and behavioral factors that contribute to prehospital delay [14,
38].
Conflicting reports exist in the literature regarding sex differences in rates of thrombolytic
administration. In two studies, eligible women were 46% to 60% less likely to receive
intravenous (IV) tPA than eligible men; however, these studies reported wide variation in the
rates of eligibility and receipt of IV tPA across hospitals within the geographic region [39,
40]. Similar results were found in a recent meta-analysis of published literature [41].
Interestingly, data from 32 academic medical centers found that women and men were equally
likely to receive IV tPA in risk-adjusted analyses [42], suggesting that the “gender gap” may
be closing, especially at larger academic centers.
According to the most recent American Heart Association statistics based on the GWTG-Stroke
program, 71.8% of men and 68% of women arriving within the first 2 h of symptom onset
received IV tPA. The difference increased further for patients arriving within 3 h of symptom
onset (59.4% vs 55.4%) [1]. This disparity in IV tPA administration is unfortunate considering
two recent studies found that IV tPA may benefit women more than men, reversing the poorer
outcomes normally seen in women compared with men [43,44•].
Carotid Disease
Sex differences also are present in other treatments for stroke beyond tPA. Female sex is
classified as a surgical risk in carotid endarterectomy [3••]. The first clinical trial of carotid
endarterectomy, the ACAS, found that women had a death rate and perioperative stroke rate
of 3.6% compared with 1.7% in men, which was confirmed by later studies [45]. Therefore,
women are less likely to have this procedure performed (0.3% vs 1.5%), which may be
appropriate. The benefit of carotid endarterectomy in women experiencing a transient ischemic
attack or nondisabling stroke also appears to dissipate within 2 weeks, after which the benefit
rapidly declines [3••]. Some researchers suggest that this is because women have a smaller
carotid artery than men (40%) [45], which may explain the lack of sex differences in the recent
CREST, in which women had no increased risk of death or stroke compared with men (4.5%
vs 4.2%) [45].
Quality of Care
The availability of the large GWTG-Stroke registry has allowed for the detection of small
differences in the treatment of male and female stroke patients throughout the United States.
Unfortunately, women seem less likely to receive defect-free care (66.3% vs 71.1%; OR, 0.86;
95% CI, 0.85–0.87), and are less likely to be discharged home (41.0% vs 49.5%; OR, 0.84;
95% CI, 0.83–0.85) [10]. These differences will need to be closely monitored over the next
decade as our population continues to age and even more women are at risk.
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Outcomes and Disability
One of the most striking disparities between men and women is the differences in disability
and recovery post-stroke. According to a recent Framingham Heart Study, women were more
disabled in various functional activities (eg, eating, dressing, grooming, transfer from bed to
chair, and walking) during the acute phase of stroke and at 3 to 6 months post-stroke (Table
1) [7]. Multiple studies recently assessed functional outcome based on the Barthel index and
found that fewer women overall were independent in activities of daily living than men [2].
Women also are more likely to be discharged into assisted-living facilities or hospices [2,7].
However, when controlling for pre-stroke functional ability, two studies found no sex
difference in achievement of independence in activities of daily living, and attributed
differences to older age and lower pre-stroke physical function [2,46].
Depression is an area of concern for stroke victims also. Women are more likely to report
depression after stroke, which can impair recovery and quality of life. Depression at baseline
has been found to be similar between the sexes; however, data from the TAIST showed that
even when adjusting for age, stroke severity, and comorbidities, women scored lower than
men, particularly in areas such as mental health status [47]. Because of the older age at the
time of stroke, women are often living alone and therefore have less social support, which
contributes to their being institutionalized at discharge [2,3••]. Based on this observation,
researchers have begun investigating social factors related to stroke risk and recovery.
Conclusions
As the population ages, the incidence rate and mortality rate of stroke in women will continue
to increase. It is imperative to address many of the aspects in stroke presentation, treatment,
and care that may differ in men and women. Attention to these differences will ensure
equivalent levels of prevention, acute treatment, and diagnostic testing in men and women.
Women are more likely to be disabled after stroke than men. The current literature indicates
that this disparity may result from the older age and poorer pre-stroke functional status of
women than men at the time of stroke onset; however, even in age-matched cohorts, overall
functional status is worse in women than men. Differences in hormone exposure, social
networks, and comorbid function may contribute to these sex differences in functional
recovery. Differences in sex-based biology also are increasingly recognized. Different
strategies (eg, social interaction, treatment of depression) may be more efficacious in women,
and rehabilitation strategies may need to be tailored to the specific needs of women post-stroke.
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Clinical Trial Acronyms
ACAS Asymptomatic Carotid Atherosclerosis Study
CREST Carotid Revascularization Endarterectomy Versus Stenting Trial
ELITE Early Versus Late Intervention Trial With Estradiol
KEEPS Kronos Early Estrogen Prevention Study
MONICA Multinational Monitoring of Trends and Determinants in Cardiovascular
Disease
TAIST Tinzaparin in Acute Ischemic Stroke Trial
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Fig. 1.
Approximate risk of stroke by age and sex. Data were compiled from available sources to
estimate the approximate risk of stroke over the life span [1•,6,48–50]
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Table 1
Differences in prevalence of stroke, incidence of stroke, disability, and mortality post-stroke between men and
women in the United States
Women Men
Prevalence (as of 2005), million 3.9 2.6
Average age of first stroke, y 72.9 68.6
Incidence
 55–64 y – 25% higher
 65–74 y – 50% higher
 75–84 y 25% higher
Disability: 3–6 mo post-stroke, unable to do independently, %
 Eating 15 9
 Dressing 37 20
 Grooming 32 17
 Transfer from bed to chair 32 13
 Walking 32 18
Mortality (as of 2005) 86,993 56,586
(Data from the American Heart Association [1•], Appelros et al. [4], and Petrea et al. [7].)
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